National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$59.95
add to cart

Rights & Permissions

topleft topright

Dietary Supplements: A Framework for Evaluating Safety (2005)
Institute of Medicine (IOM)

Citation Manager

. "Appendix J: Prototype Focused Monograph: Review of Liver-Related Risks for Chaparral." Dietary Supplements: A Framework for Evaluating Safety. Washington, DC: The National Academies Press, 2005.

Please select a format:

BibTeX EndNote RefMan


Page
437
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Dietary Supplements: A Framework for Evaluating Safety

TABLE E Nordihydroguaiaretic Acid (NDGA): Summary of Animal Studies

Species/Study Design

Results and Conclusions

Acute toxicity studies, gavage or oral administration

Toxicity Data

Species

LD50

Route

 

Rat

5.5 g/kg

Gavage (Lehman et al., 1951)

 

Mouse

4 g/kg

Gavage (Lehman et al., 1951)

 

Mouse

0.1–0.8 g/kg

i.p. (Fujii et al., 1970; Kozubik et al., 1993; Madrigal-Bujaidar et al., 1998)

 

Guinea pig 0.8 g/kg

Gavage (Lehman et al., 1951)

Rats (male, S/D), NDGA (single dose at 25 or 50 mg/kg body weight, gavage), ± indomethacin mucosa (20 mg/kg body weight, gavage), animals were sacrificed 4 hr later

NDGA enhanced indomethacin-induced mast cell degranulation in gastric

NDGA increased prostanoid activity in gastric glandular mucosa

With NDGA pretreatment, indomethacin-induced lesions in the gastric mucosa were more severe; this is a possible cytotoxic effect (Cho and Ogle, 1987)

Acute toxicity studies, other routes of administration

Rats (Wistar Albino), NDGA (1 dose at 10 μg/kg body weight, i.v.)

In a model of ischemia reperfusion injury to the liver, rats were given NDGA 5 min before reperfusion (± iloprost, 25 μg/kg i.v., given just before warm ischemia)

By histopathologic examination, liver damage was more extensive in the rats treated with NDGA compared with the control (saline-injected) animals (Okboy et al., 1992)

Mice (female, CD1), NDGA (50 mg/kg body weight, i.v.)

Pharmacokinetic analysis (using M4NDGA as a standard):

Peak plasma concentration = 14 μg/mL

Exposure (AUC) = 248 μg/mL/min

Clearance = 202 mL/(min/kg)

Volume of distribution = 3.4 L/kg

Half-life in 1st compartment = 30 min

Half-life in 2nd compartment = 135 min

NDGA appears to follow a 2-compartment pharmacokinetic model (Lambert et al., 2001)

Mice (male, CBA), NDGA (2 doses, 2-h apart, 50 mg/kg body weight, i.p.)

At 2 wk after treatments (NDGA, galactosamine, and endotoxin), histological examination of liver showed small foci of necrosis adjacent to areas of infiltration of inflammatory cells; some of this hepatic damage was due to endotoxin administration (Parry, 1993)

Page
437
Front Matter (R1-R20)
Executive Summary (1-18)
1 Introduction and Background (19-42)
2 Approaches Used by Others and Existing Safety Frameworks (43-84)
3 The Framework (85-125)
4 Categories of Scientific Evidence--Human Information and Data (126-155)
5 Categories of Scientific Evidence--Animal Data (156-174)
6 Categories of Scientific Evidence--Information About Related Substances (175-216)
7 Categories of Scientific Evidence--In Vitro Data (217-234)
8 Interactions (235-246)
9 Vulnerable Groups and Prevalance of Use (247-252)
10 Scientific Principles for Integrating and Evaluating the Available Data (253-268)
11 Applying the Framework: Case Studies Using the Prototype Safety Monographs (269-291)
12 Factors Influencing Use of the Safety Framework (292-296)
13 Findings and Recommendations (297-306)
Appendix A: Existing Frameworks or Systems for Evaluating the Safety of Other Substances (307-315)
Appendix B: Scope of Work and Comments to Initial July 2002 Framework (316-321)
Appendix C: Plant Family Information (322-355)
Appendix D: Chaparral: Prototype Monograph Summary (356-362)
Appendix E: Glucosamine: Prototype Monograph Summary (363-366)
Appendix F: Melatonin: Prototype Monograph Summary (367-371)
Appendix G: Chromium Picolinate: Prototype Monograph Summary (372-375)
Appendix H: Saw Palmetto: Prototype Monograph Summary (376-379)
Appendix I: Shark Cartilage: Prototype Monograph Summary (380-384)
Appendix J: Prototype Focused Monograph: Review of Liver-Related Risks for Chaparral (385-449)
Appendix K: Protoype Focused Monograph: Review of Anti-Androgenic Risks of Saw Palmetto Ingestion by Women (450-477)
Appendix L: Acknowledgements (478-480)
Appendix M: Biographical Sketches of Commitee Members (481-488)
Index (489-506)